Zacks Investment Research on MSN
Is BMY's deep pipeline the key to its next growth phase?
Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...
The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results